Somerset, N.J. – October 14, 2014 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced it has appointed Steven Fasman as Senior Vice President and General Counsel, effective immediately.
John Chiminski, President and CEO, Catalent Pharma Solutions said, “I am delighted that Steven Fasman has joined Catalent. He is widely respected as a talented lawyer with a proven record of leadership in results-focused environments, making him the ideal person for this important position on Catalent’s executive leadership team.”
Steven Fasman joins Catalent with an accomplished legal career and extensive experience in a broad range of industries in both private practice and corporate in-house roles. Most recently he served as Executive Vice President of Law at MacAndrews & Forbes Holdings, Inc., a private investment firm with interests in bio-technology, consumer products, banking, media, e-commerce, and other businesses. As the senior lawyer in the MacAndrews & Forbes legal department, he oversaw all legal aspects pertaining to its business transactions, including mergers and acquisitions, intellectual property, SEC filings, regulatory issues, and commercial deals.
From 2008 to 2011, he concurrently served as the Chief Legal Officer and Chief Compliance Officer for M&F Worldwide Corp., a diversified, NYSE-listed company with $1.9 billion in annual revenue.
Mr. Fasman spent his early career at the top-tier, New York City law firm of Paul, Weiss, Rifkind, Wharton & Garrison, where he focused on domestic and international litigation and regulatory proceedings.
A law-graduate of Yale University with a bachelor’s degree in math from Princeton University, Mr. Fasman is currently President and a trustee of the Jewish Board of Family & Children’s Services in New York City. He is married with two children.
+44 (0)7580 041073
+44 (0)161 728 5880
Catalent Pharma Solutions, is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com